Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GH21 in advanced solid tumors
NCT05183243Phase 1Recruiting
- Sponsor
- Genhouse Bio
- Start
- Feb 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GH21 in solid tumor (advanced stage), sponsored by Genhouse Bio. Primary endpoints: Maximum Tolerated Dose at 28 days and Safety and Tolerability at 3 years. Started Feb 2022; status: recruiting.
02
Drugs
GH21
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05183243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05183243.